Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $245.64 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| DUSA Pharmaceuticals, Inc. | $87.65 | 1 | $0 (2018) |
| Incyte Corporation | $51.90 | 2 | $0 (2024) |
| Lilly USA, LLC | $33.34 | 1 | $0 (2024) |
| Galderma Laboratories, L.P. | $25.29 | 1 | $0 (2024) |
| Arcutis Biotherapeutics, Inc. | $22.08 | 1 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $12.89 | 1 | $0 (2020) |
| Allergan, Inc. | $12.49 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $132.61 | 5 | Incyte Corporation ($51.90) |
| 2021 | $12.49 | 1 | Allergan, Inc. ($12.49) |
| 2020 | $12.89 | 1 | Sun Pharmaceutical Industries Inc. ($12.89) |
| 2018 | $87.65 | 1 | DUSA Pharmaceuticals, Inc. ($87.65) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $33.34 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $26.12 | General |
| Category: Dermatology | ||||||
| 10/23/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $25.78 | General |
| Category: Dermatology | ||||||
| 10/08/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $25.29 | General |
| 09/09/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: Dermatology | ||||||
| 08/25/2021 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.49 | General |
| Category: FACIAL AESTHETICS | ||||||
| 01/15/2020 | Sun Pharmaceutical Industries Inc. | LEVULAN KERASTICK (Drug), BLU-U | Food and Beverage | Cash or cash equivalent | $12.89 | General |
| Category: Dermatology | ||||||
| 02/08/2018 | DUSA Pharmaceuticals, Inc. | Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% (Drug), BLU-U Blue Light Photodynamic Therapy Illuminator Model 4170 | Food and Beverage | In-kind items and services | $87.65 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 13 | 13 | $3,211 | $1,068 |
| 2022 | 6 | 223 | 333 | $55,838 | $14,079 |
| 2021 | 12 | 984 | 2,066 | $351,937 | $115,794 |
| 2020 | 14 | 863 | 1,890 | $302,946 | $85,995 |
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $3,211 | $1,068 | 33.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 78 | 82 | $19,680 | $4,518 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 44 | $15,532 | $3,483 | 22.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 24 | 25 | $6,700 | $2,451 | 36.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 34 | 35 | $6,720 | $1,387 | 20.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 14 | 14 | $4,413 | $1,334 | 30.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 29 | 133 | $2,793 | $906.98 | 32.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 211 | 320 | $109,760 | $34,655 | 31.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 242 | 342 | $79,686 | $27,468 | 34.5% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 94 | 119 | $27,260 | $13,764 | 50.5% |
| 17000 | Destruction of skin growth | Office | 2021 | 141 | 216 | $41,008 | $10,537 | 25.7% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 77 | 92 | $29,829 | $9,196 | 30.8% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 116 | 842 | $15,998 | $5,954 | 37.2% |
| 12032 | Repair of wound (2.6 to 7.5 centimeters) of the scalp, underarms, trunk, arms, and/or legs | Office | 2021 | 13 | 14 | $16,757 | $4,567 | 27.3% |
| 11104 | Punch biopsy of single skin lesion | Office | 2021 | 29 | 32 | $13,632 | $4,478 | 32.9% |
| 17004 | Destruction of 15 or more premalignant skin growths | Office | 2021 | 13 | 18 | $8,856 | $2,997 | 33.8% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 16 | 24 | $5,424 | $1,352 | 24.9% |
| 11900 | Injection of up to 7 skin growths | Office | 2021 | 14 | 16 | $3,510 | $794.39 | 22.6% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2021 | 18 | 31 | $217.00 | $31.48 | 14.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 209 | 297 | $97,713 | $27,256 | 27.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 148 | 202 | $45,450 | $11,810 | 26.0% |
| 17000 | Destruction of skin growth | Office | 2020 | 143 | 198 | $41,008 | $9,562 | 23.3% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 63 | 81 | $17,680 | $9,208 | 52.1% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 62 | 80 | $27,005 | $7,192 | 26.6% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 119 | 881 | $15,858 | $5,600 | 35.3% |
About Dr. Bryan Cho, MD
Dr. Bryan Cho, MD is a Dermatology healthcare provider based in Mountain View, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1891811600.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bryan Cho, MD has received a total of $245.64 in payments from pharmaceutical and medical device companies, with $132.61 received in 2024. These payments were reported across 8 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($245.64).
As a Medicare-enrolled provider, Cho has provided services to 2,083 Medicare beneficiaries, totaling 4,302 services with total Medicare billing of $216,936. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Mountain View, CA
- Active Since 03/22/2007
- Last Updated 12/13/2011
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1891811600
Products in Payments
- Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% (Drug) $87.65
- OPZELURA (Drug) $51.90
- TALTZ (Drug) $33.34
- Zoryve (Drug) $22.08
- LEVULAN KERASTICK (Drug) $12.89
- BOTOX (Biological) $12.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Mountain View
Jenny Murase, M.d, M.D
Dermatology — Payments: $533,223
Amit Pandya, Md, MD
Dermatology — Payments: $362,467
Dr. Duke Khuu, Md Faad, MD FAAD
Dermatology — Payments: $42,122
Krystle Wang, M.d, M.D
Dermatology — Payments: $37,527
Dr. Olga Afanasiev, Md, Phd, MD, PHD
Dermatology — Payments: $9,247
Anjali Morales, Md, MD
Dermatology — Payments: $7,103